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The Nobel Prize in Medicine in 2009 was awarded to Eliza-
eth Blackburn, Carol Greider and Jack Szostak for discovering
he molecular structure of the far ends of chromosomes, called
elomeres (Fig. 1), andhowtheseprotect chromosomes fromdegra-
ation. Their discoveries shed light on a basic biologicalmechanism
hich stimulated research in a new exciting ﬁeld aiming to explore
he role of telomeres in normal ageing, cancer and age-related dis-
ase pathology.
Elizabeth Blackburn ﬁrst announced the identiﬁcation of the
epeated sequence of DNA in telomeres at a conference in 1980
nd together with Jack Szostak in 1982 revealed that telomeres
onstitute a fundamental mechanism offering protection to chro-
osomes from degradation throughout different species [1]. In
984 Carol Greider working with Elizabeth Blackburn discovered
he enzyme which forms telomeric sequences [2,3]. This enzyme
revents telomere shortening with cell division, which otherwise
akes place due to the incapability of DNA polymerase to fully
opy the very end sequences of chromosomes during DNA repli-
ation, the so-called end-replication problem [4]. The impact of
lackburn’s, Greider’s and Szostak’s work during the early 1980s
s indicated by the increasing rate of publications in the ﬁeld of
elomeres thereafter (Fig. 2).
We now know that telomeres’ biological function goes beyond
he protection of chromosome ends from degradation or fusion,
laying an important role in the cell’s ageing process [5]. The length
f telomeres serves as a mechanism of normal cell senescence [6].
n somatic cells, where the enzyme telomerase is not expressed,
elomeres become shorter with each cell division, due to the end-
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Open access under CC BY-NC-ND license.replication problem. Once the length reduces below a critical value
replicative senescence, also called the Hayﬂick limit, is induced [7].
The rate of telomere shortening in telomerase negative cells is not
only dependent on the number of cell divisions, but also on DNA
damage. The ends of telomeres constitute 3′ single-strand over-
hangs which are prone to single-strand breaks, particularly those
caused by oxidative damage, due to their G-rich content. The accu-
mulation of suchbreaks along the telomeres leads to additional loss
during replication [8,9]. Therefore, the lengthof telomeres indicates
the replicative capacity andcumulativegenomicdamageof somatic
cells, reﬂecting in this way the tissue’s “biological age”.
In recent years, the role of telomere length in the pathology of
cardiovascular disease (CVD) anddiabetes,where tissue ageing and
senescence play major roles, has attracted a continuously growing
research interest, and in the last two years alone six articles on
telomere length have been published in Atherosclerosis. An article
by Adaikalakoteswari et al. in the November 2007 issue associ-
ated shorter leukocyte telomere length (LTL)with impaired glucose
tolerance, type 2 diabetes (T2D) and atherosclerotic plaques in
T2D patients [10]. In June 2008, Satoh et al. showed that telom-
ere lengthwas shorter and telomerase activity lower in endothelial
progenitor cells from patients with coronary heart disease (CHD)
and evenmore reduced in CHD patients with metabolic syndrome.
At the same time, oxidative DNA damage in these subjects dis-
played the opposite trend [11]. Following this, LTL was shown to
negatively correlate with homocysteine levels by Richards et al.
[12] and to positively correlate with HDL in the study of Chen
et al. [13]. In a recent issue of Atherosclerosis, Olivieri et al. [14]
showed that LTL is shorter in T2D patients compared to healthy
subjects and even shorter in T2D patients with CHD.More recently,
in this issue, our study [15] conﬁrms the shorter LTL in T2Dpatients
and also correlates LTL with plasma oxidative stress and variation
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. Telomere length in cardiovascular disease
The association of telomere lengthwith atherosclerosis andCVD
as been supported by a large number of studies over the last few
ears [16–21]. Indicative of this effect is that CHD patients have
ean LTL equivalent to that of 11 years older healthy subjects,
s shown in the study of Brouilette et al. [19], which reﬂects the
iological ageing of the vascular wall (Fig. 3).
The evidence so far, suggests that in atherosclerosis telomere
ength probably contributes as a primary abnormality. In support
f this are studies showing that family history of CHD is in part
nherited through short LTL [22,23], most importantly the prospec-
ive studies associating baseline LTL with the risk to develop CVD
20,21,24], as well as the association of LTL with markers of sub-
linical CVD, such as intima-media thickness [10,21].
For pragmatic reasons,most of the studies have used LTL instead
f vascular wall cell telomere length. However, Wilson et al. [25]
ave shown that LTL is a good predictor of vascular wall telom-
re length. Nonetheless, as LTL is only a surrogate of the telomere
ength in the cells contributing to atherosclerosis, it is likely that
ig. 2. The rate of publications in the ﬁeld of telomeres over the last 40 years, using
ata from the “Web of Science”.ation of telomeres.
the real effect on CHD risk is greater than the observed when using
LTL.
2. Telomere length in diabetes
It is now becoming apparent that type 2 diabetes (T2D) is also
characterised by shorter telomeres [10,26,14,15]. It is not clear
though, from the cross-sectional data available so far, whether the
observed shorter telomeres in diabetes are a cause or consequence
of the disease. Although the data are scarce, shorter telomeres have
also been observed in type 1 diabetes patients [27]. The etiology
of the disease in type 1 diabetes is in part different with that in
type 2, although in both cases beta cell failure is the ﬁnal trigger.
Thus, one could speculate that critically short telomeres contribute
to the onset of diabetes by eliciting senescent phenotypes in beta
cells. However, in the case of type 1 diabetes again the data are
cross-sectional, so the possibility that short telomeres are a result
of the disease cannot be excluded. There is a need for a prospective
study of the risk for diabetes in respect to telomere length in order
to address this question.
Nevertheless, telomere length seems like a useful marker for
T2D since it is associated with its progression. In the study of
Adaikalakoteswari et al. telomeres were shorter in patients with
Fig. 3. Schematic presentation of LTL decrease with age in CHD cases (solid line)
and controls (dashed line). The double line illustrates the biological age gap between
cases and controls.
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nly impaired glucose tolerance compared to controls and even
horter in T2D patients [10]. In addition, telomere shortening has
een linked to diabetes complications, such as diabetic nephropa-
hy [28], microalbuminuria [29] and epithelial cancers [30], while
elomere shortening seems to be attenuated in patients with well-
ontrolled diabetes [27].
. Telomere length in co-existence of cardiovascular
isease and type 2 diabetes
A very interesting ﬁnding, conﬁrmed in independent studies, is
hat patients with diabetes or prediabetes exhibiting atheroscle-
otic manifestations have the shortest telomeres compared to
atientswith diabetes or CVD alone. Adaikalakoteswari et al. found
hat among T2D patients those with atherosclerotic plaques had
he shorter telomeres [10]. The study of Olivieri et al. [14] showed
hat T2D patients withMI had shorter telomeres than T2D subjects
ree of MI and in our study [15], among the T2D subjects those
ith CHD had the shorter telomeres. Finally, Satoh et al. showed
hat CHD patients with metabolic syndrome had shorter telom-
res than CHD patients without metabolic syndrome [11]. These
bservations suggest that substantially decreased telomere length,
ither caused by the common risk factors between CVD and dia-
etes and/or inherited short telomeres, possibly reﬂects greater
issue ageing and greater prevalence of senescent phenotypes in
arious tissues, including the vascular wall and pancreatic islets.
herefore, LTL might be a very useful marker of tissue ageing and
rogression of both CVD and diabetes.
. Telomere length determinants
As to what determines telomere length, the data so far suggest
contribution of oxidative stress to the observed shorter LTLs in
atients. Adaikalakoteswari et al. [10] found a negative correlation
ith a lipid peroxidation marker, Satoh et al. [11] with oxidative
NA damage and our study [15] showed a negative correlation
ith plasma oxidative stress and association with variation in a
ene regulatingmitochondrial reactive oxygen species production.
he oxidative-induced telomere shortening has been established
ith in vitro experiments [8,9]. What is not clear yet is which
actors, and to what extent contribute to the high levels of oxida-
ive stress. The inverse correlation of LTL with variables reﬂecting
he glycaemic state of patients in the study of Olivieri et al. [14]
nd the attenuation of telomere shortening in patients with good
lycaemic control, as showedbyUziel et al. [27], suggest thathyper-
lycaemia might be driving the oxidative-induced telomere loss
n diabetes. To this end the contribution of inﬂammation cannot
e excluded, although many studies, including Oliveiri’s et al. and
urs, have failed to detect an association with inﬂammatory mark-
rs [14,15]. On the other hand, the rate of telomere shortening was
ssociated with longitudinal cumulative HDL in the study of Chen
t al. This suggests that LTL probably reﬂects the lifelong accu-
ulating burden of increased oxidative stress and inﬂammation,
hereas instant markers of these are not as representative [13].
hat is determining the rate of oxidative stress-induced telom-
re shortening and if inﬂammation contributes to this effect needs
o be further investigated with in vitro experiments. Worthy of
emark is that in the study of Chen et al. [13] the rate of telom-
re shortening was dependent on the baseline telomere length,
hich is also supported by the ﬁndings of Nordfjall et al. [31].
hus, it is possible that in longer telomeres, greater loss per cell
ivision is more likely to occur. This, coupled with the high heri-
ability in telomere length shown by twin studies [32,33], supports
he hypothesis that telomere length is, to a large extent, geneti-
ally determined. It also supports the theory, that predisposition to
[
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CVD and/or diabetes might be expressed through inherited short
telomeres.
5. Future work
Telomere lengthmayprove tobe veryuseful in themanagement
and possibly the prediction of CVD and diabetes, representing the
contribution of tissue ageing to their pathology. In order to explore
this potential, further studies are needed to investigate in more
depthwhat is the role of telomeres in the development of these dis-
eases andwhether it is important or not. Speciﬁcally, there is a need
for prospective studies to establishwhether telomere shortening is
causative and examine the usefulness of LTL in predicting disease
risk, especially for diabetes, since there is no previous record. In
addition, it remains to be conﬁrmed if LTL is a good surrogate mea-
sure of beta cells’ telomere length, as it has been shown for the
vascular wall cells, before examining whether it is a useful marker
in T2D. More importantly, there is a need to shed light on the basic
biological functions of telomeres, like the mechanism involved in
the trigger of cell senescence by telomere length or structure, how
this is regulated and the possible interactions of telomeres with
other chromosome regions.
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